Article

Daily Medication Pearl: Galcanezumab-gnlm (Emgality)

Medication Pearl of the Day: Galcanezumab-gnlm (Emgality)

Indication: Galcanezumab-gnlm (Emgality) is a calcitonin-gene related peptide (CGRP) antagonist indicated in adults for the preventive treatment of migraine and treatment of episodic cluster headache.

Insight:

Dosing: Migraine recommended dosage 240 mg loading dose, administered as 2 consecutive injections of 120 mg each, followed by monthly doses of 120 mg.

Dosage forms: Injection 120 mg/mL solution in a single-dose prefilled pen.

Adverse events: The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Mechanism of action: Galcanezumab-gnlm is a humanized monoclonal antibody that binds to the CGRP ligand and blocks its binding to the receptor.

Manufacturer: Eli Lilly

References:

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit: AwieDarwis | stock.adobe.com
Image credit: viperagp | stock.adobe.com
Image credit:  kitsawet | stock.adobe.com
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com